Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0482Keywords:
sarcoidosis, subtypes, organ involvement, immunosuppressionAbstract
Cutaneous sarcoidosis presents with diverse morphologies, yet comparative data on systemic involvement, disease course and treatment response across subtypes remain limited. We conducted a 2-centre cross-sectional study including patients with histologically confirmed sarcoidosis identified through ICD codes, stratified into patients with and without cutaneous involvement and further by cutaneous subtype. Demographics, extracutaneous organ involvement, treatment response, clinical course and the organ leading to initial diagnosis were analysed. Among 125 patients (median age 53 years; 57% female), 99 had cutaneous sarcoidosis and 26 had no skin involvement. All major subtypes of cutaneous sarcoidosis were represented: plaque (39), papular (19), scar (15), subcutaneous (13) and lupus pernio (4); erythema nodosum (9) represented acute disease. Papular sarcoidosis (19) showed the mildest systemic involvement. Lymph nodes (64%) and lungs (48%) were most frequently affected with subtype specific variation. Skin lesions led to diagnosis in 78% of cases. Remission with topical therapy was rare (11%), whereas systemic glucocorticoids (21%) and other immunosuppressants (37%) showed higher response rates; sirolimus (11%), hydroxychloroquine (10%) and TNF inhibitors (8%) were most effective. Relapse occurred in 40% and 46% required long-term systemic therapy. Cutaneous sarcoidosis subtypes differ markedly in systemic involvement, treatment response and disease course, supporting biological heterogeneity and the need for individualized management.
Downloads
References
Iannuzzi MC, Rybicki BA, Teirstein AS. . Sarcoidosis. N Engl J Med 2007; 357: 2153–2165. DOI: https://doi.org/10.1056/NEJMra071714
Krausgruber T, Redl A, Barreca D, Doberer K, Romanovskaia D, Dobnikar L, et al. Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. Immunity 2023; 56: 289–306. DOI: https://doi.org/10.1016/j.immuni.2023.01.014
Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201: e26–e51. DOI: https://doi.org/10.1164/rccm.202002-0251ST
Sève P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S, et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells 2021; 10: 766. DOI: https://doi.org/10.3390/cells10040766
Mañá J, Rubio-Rivas M, Villalba N, Marcoval J, Iriarte A, Molina-Molina M, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine 2017; 96: e7595. DOI: https://doi.org/10.1097/MD.0000000000007595
Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255–263. DOI: https://doi.org/10.1183/09031936.00002512
Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079. DOI: https://doi.org/10.1183/13993003.04079-2020
Lower EE, Sturdivant M, Grate L, Baughman RP. Use of third-line therapies in advanced sarcoidosis. Clin Exp Rheumatol 2020; 38: 834–840.
Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med 2020; 93: 187–195.
Caplan A, Rosenbach M, Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med 2020; 41: 689–699. DOI: https://doi.org/10.1055/s-0040-1713130
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885–1889. DOI: https://doi.org/10.1164/ajrccm.164.10.2104046
Costabel U, Guzman J, Baughman RP. Systemic evaluation of a potential cutaneous sarcoidosis patient. Clin Dermatol 2007; 25: 303–311. DOI: https://doi.org/10.1016/j.clindermatol.2007.03.008
Hanno R, Needelman A, Eiferman RA, Callen JP. Cutaneous sarcoidal granulomas and the development of systemic sarcoidosis. Arch Dermatol 1981; 117: 203–207. DOI: https://doi.org/10.1001/archderm.1981.01650040019012
Boch K, Langan EA, Zillikens D, Ludwig RJ, Kridin K. Evaluation of clinical and laboratory characteristics of patients with cutaneous sarcoidosis: a single-center retrospective cohort study. Front Med 2022; 9: 980507. DOI: https://doi.org/10.3389/fmed.2022.980507
Karadağ AS, Parish LC. Sarcoidosis: a great imitator. Clin Dermatol 2019; 37: 240–254.
Karakaya B, Kaiser Y, van Moorsel CHM, Grunewald J. Löfgren’s syndrome: diagnosis, management, and disease pathogenesis. Semin Respir Crit Care Med 2017; 38: 463–476. DOI: https://doi.org/10.1055/s-0037-1602380
Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9: 155–161. DOI: https://doi.org/10.2165/00128071-200809030-00003
Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 2012; 66: 699. DOI: https://doi.org/10.1016/j.jaad.2011.11.965
Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Patterson KC, et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol 2015; 151: 1317–1322 DOI: https://doi.org/10.1001/jamadermatol.2015.2008
Karadağ AS, Parish LC. Clinical phenotypes of cutaneous sarcoidosis: a review. Clin Dermatol 2019; 37: 660–667. DOI: https://doi.org/10.1016/j.clindermatol.2019.01.005
Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Baughman RP, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19–27.
Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol 2013; 149: 550. DOI: https://doi.org/10.1001/jamadermatol.2013.60
Stjepanovic M, Mihailovic-Vucinic V, Gvozdenovic BS, Milin-Lazovic J, Belic S, Djurdjevic N, et al. King’s Sarcoidosis Questionnaire (KSQ) - validation study in Serbian speaking population of sarcoidosis patients. PLoS One 2023; 18: e0273126. DOI: https://doi.org/10.1371/journal.pone.0273126
Belperio JA, Shaikh F, Abtin FG, Fishbein MC, Weigt SS, Saggar R, et al. Diagnosis and treatment of pulmonary sarcoidosis: a review. JAMA 2022; 327: 856–867. DOI: https://doi.org/10.1001/jama.2022.1570
Lo Schiavo A, Ruocco E, Gambardella A, O’Leary RE, Gee S. Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol 2014; 32: 646–653. DOI: https://doi.org/10.1016/j.clindermatol.2014.04.012
Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med 2021; 385: 1018–1032. DOI: https://doi.org/10.1056/NEJMra2101555
Zhang H, Costabel U, Dai H. The role of diverse immune cells in sarcoidosis. Front Immunol 2021; 12: 788502. DOI: https://doi.org/10.3389/fimmu.2021.788502
Monast CS, Li K, Judson MA, Baughman RP, Wadman E, Watt R, et al. Sarcoidosis extent relates to molecular variability. Clin Exp Immunol 2017; 188: 444–454. DOI: https://doi.org/10.1111/cei.12942
Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51: 1700991. DOI: https://doi.org/10.1183/13993003.00991-2017
Kahlmann V, Janssen Bonás M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. N Engl J Med 2025; 393: 231–242. DOI: https://doi.org/10.1056/NEJMoa2501443
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
